Professional Documents
Culture Documents
US V Abbott Labs - Baby Formula Consent Decree
US V Abbott Labs - Baby Formula Consent Decree
US V Abbott Labs - Baby Formula Consent Decree
Plaintiff,
v. Case No.
Defendants.
_________________________________________/
Plaintiff, the United States of America, by its undersigned counsel and on behalf of the
United States Food and Drug Administration (“FDA”), having filed a Complaint for Permanent
Nutrition, and Keenan S. Gale, TJ Hathaway, and Lori J. Randall, individuals, (collectively,
“Defendants”), and Defendants having appeared and having consented to the entry of this
Consent Decree of Permanent Injunction (the “Decree”) without contest and before any
testimony has been taken, and the United States of America having consented to this Decree,
1. This Court has jurisdiction over the subject matter and over all parties to this
action under 28 U.S.C. §§ 1331 and 1345, 21 U.S.C. § 332, and its inherent equitable authority.
2. The Complaint states a cause of action against Defendants under the Federal
interstate commerce articles of food that are adulterated within the meaning of 21 U.S.C.
§ 342(a)(4).
interstate commerce articles of food, namely infant formula as defined in 21 U.S.C. § 321(z), that
are adulterated within the meaning of 21 U.S.C. § 350a(a)(3), 21 U.S.C. § 350a(b)(2), and 21
articles of food that are held for sale after shipment of one or more of their components in
articles of food, namely infant formula as defined in 21 U.S.C. § 321(z), that are held for sale
after shipment of one or more of their components in interstate commerce to become adulterated
Defendants’ officers, agents, employees, attorneys, successors, and assigns, and any and all
persons in active concert or participation with any of them (including individuals, partnerships,
corporations, subsidiaries, and “doing business as” entities) who are involved with the
B. “CGMP Regulations for Human Food” shall refer to the current good
2
Case 1:22-cv-00441 ECF No. 2-1, PageID.26 Filed 05/16/22 Page 3 of 33
Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human
Food);
finished products manufactured at the Sturgis Facility and in Defendants’ possession, custody, or
control as of March 18, 2022, the close of FDA’s inspection at Defendants’ facilities located at
preparing, packing, labeling, holding, and/or distribution at or from the Sturgis Facility of any
infant formula, as that term is defined in 21 U.S.C. § 321(z), in powdered form, except for
Inventory Products defined in paragraph 7(E) and products subject to Specialty Operations
preparing, packing, labeling, holding, and/or distribution at or from the Sturgis Facility of any
or
3
Case 1:22-cv-00441 ECF No. 2-1, PageID.27 Filed 05/16/22 Page 4 of 33
age) that serves similar nutritional purposes as any formulation of powdered infant formula
Specialty Operations
8. Subject to paragraph 11(A), upon entry of this Decree, Defendants and each and
all of their Associated Persons who have received actual notice of this Decree are permanently
restrained and enjoined under 21 U.S.C. § 332(a), and the inherent equitable authority of this
Court, from conducting Specialty Operations, unless all the following conditions are met:
independent person or persons (“Expert”) who is without any personal or financial ties (other
than a retention agreement or agreements to satisfy the requirements of this Decree and/or to
perform other consulting or testing work for Abbott Nutrition) to Defendants or their families,
Sturgis Facility to ensure that Defendants’ products are manufactured, processed, prepared,
packed, labeled, held, and distributed in compliance with this Decree, the Act, the CGMP
Regulations for Human Food, and the Infant Formula CGMP Regulations; and
facilities, methods, processes, and controls are continuously operated and administered in
conformity with this Decree, the Act, and its implementing regulations;
4
Case 1:22-cv-00441 ECF No. 2-1, PageID.28 Filed 05/16/22 Page 5 of 33
of the Expert within two days after retaining the Expert, and, in coordination with the Expert,
Defendants shall:
controls) for production equipment and processing environments, and validate the test method
for moisture verification used to assess dryness after the dry-out procedures for production
equipment and processing environments. Where applicable, Defendants may rely on completed
action described in Defendants’ response(s) to the FDA Form-483 issued on March 18, 2022
(“Form-483 Response”);
production equipment and processing environments (using the verified dry-out procedures and
the validated test method), followed by environmental testing for pathogens in the processing
environment. Where applicable, Defendants may rely on completed actions already conducted in
with the Expert’s report documenting completion of the verification and validation activities and
equipment and processing environments, then Defendants shall ensure that any cleaning,
sanitizing, dry-out, and/or environmental testing during the pendency of Specialty Operations of
equipment and processing environments that are not part of Specialty Operations is
accomplished in a manner that protects against contamination of the specified equipment and
processing environments (and utensils therein) that are part of Specialty Operations;
5
Case 1:22-cv-00441 ECF No. 2-1, PageID.29 Filed 05/16/22 Page 6 of 33
Operations, Defendants shall ensure that a qualified individual in Defendants’ quality unit
reviews the batch record, the test results for in-process and finished product, and the
environmental monitoring results that pertain to the product lot, and certifies in writing to FDA
Operations consists of routine sampling and, when appropriate, investigative sampling, and that a
Specialty Operations and shall analyze the powdered infant formula samples for Cronobacter
spp. and Salmonella spp., in the manner specified in 21 C.F.R. § 106.55, and shall analyze the
powdered non-infant product samples for Salmonella spp. If any test of in-process or finished
product detects the presence of Cronobacter spp. and/or Salmonella spp., Defendants shall:
(1) Cease production at the earliest time practicable and, in any event,
no later than the completion of any batch then in progress, dispose of the affected in-process
and/or finished product batch, conduct a thorough contamination-source determination (i.e., root-
cause analysis), and adequately remediate the processing equipment and environment.
Defendants shall maintain records of all the steps taken pursuant to this paragraph and shall
make the records available to FDA immediately upon request. After a cessation of production
pursuant to this paragraph, Defendants shall not resume production unless and until they receive
6
Case 1:22-cv-00441 ECF No. 2-1, PageID.30 Filed 05/16/22 Page 7 of 33
written notice from FDA that Defendants may resume production. Within fifteen days after
receipt of Defendants’ written request to resume production, unless FDA determines that, based
on the complexity of the issues, a longer time frame is necessary, in which case FDA can give
Defendants notice that FDA needs an additional fifteen days to complete its review, FDA will
review Defendants’ request to resume production and provide written notification to Defendants
either permitting resumption or explaining the basis for FDA’s decision not to permit resumption
of production, including the concerns with Defendants’ submission. After addressing all
Defendants may submit a new request to resume production, and the process described in
paragraph 8(G)(1) shall be repeated until Defendants receive written notification from FDA that
(2) Forward the test results detecting the presence of Cronobacter spp.
and/or Salmonella spp. in in-process and/or finished product to FDA within twenty-four hours
after receipt by Defendants (along with a written statement confirming that Defendants have
ceased production in accordance with paragraph 8(G)(1)), speciate each Cronobacter spp. isolate
positive test result to FDA within twenty-four hours of receipt by Defendants; and
under appropriate storage conditions for three years from the date of the test result detecting the
presence of Cronobacter sakazakii and/or Salmonella spp. in that isolate, and each isolate is to
7
Case 1:22-cv-00441 ECF No. 2-1, PageID.31 Filed 05/16/22 Page 8 of 33
products, including shipping documents and the following information for the product
distributed: the product name; the product size and configuration if variations exist; the batch,
lot, and manufacturing codes; and the names of customers to whom the product is shipped, along
with quantities shipped to each such customer. Defendants shall make the records described in
destroy all Inventory Products defined in paragraph 7(E) that have not been distributed within
fifteen days after Defendants initiate production under Specialty Operations. The parties may
mutually agree in writing to modify this fifteen-day time frame, which modification may be
granted without seeking leave of Court. To the extent that Defendants are under a separate legal
obligation to preserve all or a portion of the Inventory Products, Defendants shall be permitted to
segregate and retain such Inventory Products for the duration of such preservation obligation.
Other Operations
9. Upon entry of this Decree, Defendants and each and all of their Associated
Persons who have received actual notice of this Decree are permanently restrained and enjoined
under 21 U.S.C. § 332(a), and the inherent equitable authority of this Court, from conducting
of this Decree;
B. Defendants shall ensure that the Sturgis Facility and equipment therein:
(1) are cleaned and sanitized to render them suitable for manufacturing, processing, preparing,
packing, labeling, holding, and distributing articles of food in accordance with this Decree, the
8
Case 1:22-cv-00441 ECF No. 2-1, PageID.32 Filed 05/16/22 Page 9 of 33
Act, and its implementing regulations; and (2) will be continuously maintained in a sanitary
condition;
C. Defendants shall ensure that the Expert retained under paragraph 8(A):
Sturgis Facility identified in the FDA Form-483 issued on March 18, 2022, and all records
related to the detection of Cronobacter spp. and/or Salmonella spp. in the environment or in-
process or finished product at the Sturgis Facility from September 2019 to the present;
procedures including, but not limited to, sanitation standard operating procedures for receiving,
(“Sanitation Plan”) to verify that the Sanitation Plan complies with the CGMP Regulations for
Human Food and the Infant Formula CGMP Regulations and adequately: (a) establishes
sanitation controls, monitoring procedures, and corrective actions for: (i) manufacturing
processes; (ii) cleaning (including, but not limited to, cleaning in place), sanitizing, and dry-out
operations (including, but not limited to, verified dry-out procedures and validated test methods
for dry-out of production equipment and processing environments); and (iii) facilities (including,
but not limited to, building construction and maintenance to ensure, among other things,
adequate water management) and equipment and utensils contained therein; (b) addresses the
risks of microbiological contamination from contaminants including, but not limited to,
pathogens such as Cronobacter sakazakii and Salmonella spp.; and (c) protects against the
contamination of food and food-contact surfaces and prevents insanitary conditions at the Sturgis
Facility;
9
Case 1:22-cv-00441 ECF No. 2-1, PageID.33 Filed 05/16/22 Page 10 of 33
environmental monitoring and testing program (“Environmental Monitoring Plan”) to verify that
the Environmental Monitoring Plan complies with the requirements in paragraph 11(G);
sampling and testing program (“Product Monitoring Plan”) to verify that the Product Monitoring
training program (“Employee Training Program”) (in English and any other language necessary
to effectively convey the substance of the training) that addresses: (a) maintaining sanitation,
conducting adequate sampling and analysis, avoiding bacterial contamination, and controlling
pathogens; and (b) the CGMP Regulations for Human Food and the Infant Formula CGMP
Regulations, and the requirements in the Sanitation Plan, the Environmental Monitoring Plan,
and the Product Monitoring Plan. The Employee Training Program shall include training for
(including, but not limited to, buildings and equipment and utensils contained therein) and the
methods, processes, and controls used to manufacture, process, prepare, pack, label, hold, and
monitoring tests, and inspected the Sturgis Facility (including, but not limited to, buildings and
equipment and utensils contained therein) and the methods, processes, and controls used to
manufacture, process, prepare, pack, label, hold, and distribute articles of food;
10
Case 1:22-cv-00441 ECF No. 2-1, PageID.34 Filed 05/16/22 Page 11 of 33
Facility identified in the FDA Form-483 issued on March 18, 2022, and any deficiencies
identified during the Expert’s record review of the detection of Cronobacter spp. and/or
Salmonella spp. in the environment or in any article of food at the Sturgis Facility (including
samples collected during production under Specialty Operations), from September 2019 to the
present, specifying each deficiency and Defendants’ corrections thereof. Where applicable, the
Expert may refer to any completed or ongoing action described in Defendants’ Form FDA-483
Response; and
facilities, methods, processes, and controls (including the Sanitation Plan, the Environmental
Monitoring Plan, and the Product Monitoring Plan) are: (i) in compliance with this Decree, the
Act, and its implementing regulations; and (ii) adequate to ensure that Defendants’ products are
manufactured, processed, prepared, packed, labeled, held, and distributed in compliance with this
Decree, the Act, the CGMP Regulations for Human Food, and the Infant Formula CGMP
Regulations; and
findings, with supporting documentation, and submits the certification, detailed report, and
supporting documentation to Defendants and FDA concurrently, within fifteen days after
person with personal knowledge of the facts, stating the fact and manner of compliance with the
provisions of paragraphs 9(A) and 9(B). Defendants shall also submit the Sanitation Plan, the
Environmental Monitoring Plan, the Product Monitoring Plan, and the Employee Training
11
Case 1:22-cv-00441 ECF No. 2-1, PageID.35 Filed 05/16/22 Page 12 of 33
Program certified by the Expert pursuant to this paragraph to FDA for review and concurrence,
and receive written notification of concurrence from FDA. Within twenty days after receipt of
the Expert-certified plans (the Sanitation Plan, the Environmental Monitoring Plan, the Product
Monitoring Plan, and the Employee Training Program), unless FDA determines that a longer
time frame is necessary, in which case FDA can give Defendants notice that FDA needs an
additional twenty days to complete its review, FDA will review the Expert-certified plans and
provide written notification to Defendants either concurring with the plans or explaining the
basis for FDA’s decision not to concur with any plan(s), including the concerns with Defendants’
submission. After addressing all concerns described in FDA’s written notification of a decision
not to concur, Defendants shall submit a revised plan to FDA for review and concurrence.
Within fifteen days after receipt of a revised plan, unless FDA determines that a longer time
frame is necessary, in which case FDA can give Defendants notice that FDA needs an additional
fifteen days to complete its review, FDA will review the revised plan and provide written
notification to Defendants either concurring with the revised plan or explaining the basis for
FDA’s decision not to concur with the revised plan, including the concerns with Defendants’
submission. This process shall be repeated until Defendants receive written notification of
concurrence from FDA. In no circumstance shall FDA’s silence be construed as a substitute for
written notification.
General Provisions
10. Subject to the exception described in this paragraph, within twenty-five days after
entry of this Decree, Defendants shall destroy all articles of food that Defendants recalled prior
to the date of entry of this Decree (“recalled articles”). Defendants shall give notice to FDA that,
under FDA’s supervision, Defendants are prepared to destroy the recalled articles and shall
12
Case 1:22-cv-00441 ECF No. 2-1, PageID.36 Filed 05/16/22 Page 13 of 33
specify the proposed time, place, and method of destruction. Defendants shall not commence, or
permit any other person to commence, destruction until they have received written authorization
substitute for written notification. Within fifteen days after receiving authorization from FDA to
compliance with this provision. Defendants shall not dispose of any recalled article in a manner
contrary to the provisions of the Act, any other federal law, any court order, or the laws of any
state or Territory, as defined in the Act, in which the recalled articles are disposed. Defendants
shall bear the costs of destruction and the costs of FDA’s supervision at the rates specified in
paragraph 17. To the extent that Defendants are under a separate legal obligation to preserve all
or a portion of the recalled products, Defendants shall be permitted to segregate and retain such
11. After receiving written concurrence from FDA under paragraph 9(D), Defendants
the Environmental Monitoring Plan, and the Product Monitoring Plan approved by FDA under
paragraph 9(D) and shall ensure that all powdered products at the Sturgis Facility are produced
under conditions and practices that comply with these plans and the remaining provisions of this
Decree;
qualified individual in Defendants’ quality unit reviews the batch record, the test results for in-
process and finished product, and the environmental monitoring results that pertain to the
product lot, and certifies in writing that such lot meets all specifications. Defendants shall
13
Case 1:22-cv-00441 ECF No. 2-1, PageID.37 Filed 05/16/22 Page 14 of 33
maintain copies of all certifications required by this paragraph at the Sturgis Facility, in a
location where the certifications are readily available for reference and inspection by FDA;
paragraph 9(D), Defendants shall assign continuing responsibility for implementing and
the Sturgis Facility in a sanitary condition and implement appropriate corrective actions, and
Defendants provide such person(s) with the authority and resources to achieve any necessary
corrective action. Defendants shall provide to FDA, in writing, the identities, titles, and
qualifications of the individual(s) assigned responsibility under this paragraph within ten days
paragraph 9(D), Defendants shall ensure that the FDA-approved Sanitation, Environmental
Monitoring, and Product Monitoring Plans are available and accessible (in English and any other
language necessary to effectively convey the substance of these documents) to their officers,
employees, and all other persons who perform duties at the Sturgis Facility;
paragraph 9(D), Defendants shall train their employees, and all other persons who perform duties
at the Sturgis Facility, in accordance with the FDA-approved Employee Training Program, to
ensure that the individuals who receive, manufacture, process, prepare, pack, label, hold, or
distribute articles of food are qualified to perform their assigned duties. Defendants shall submit
documentation to FDA demonstrating that they have adequately trained all persons who perform
duties at the Sturgis Facility in accordance with the Employee Training Program;
14
Case 1:22-cv-00441 ECF No. 2-1, PageID.38 Filed 05/16/22 Page 15 of 33
F. Defendants shall provide training to each new employee within five days
after the new employee commences duties at the Sturgis Facility, and provide ongoing training
programs for existing employees, in accordance with the FDA-approved Employee Training
Program;
accordance with the Environmental Monitoring Plan to demonstrate that the Sanitation Plan is
consistently followed to provide systematic control over pathogens, including Cronobacter spp.
(1) Environmental monitoring shall include, but not be limited to: (a)
collecting samples from equipment and production areas that may pose a high risk of
prepared, packed, labeled, held, or distributed; and additional areas that may be reservoirs for
to FDA; (c) implementing remedial action, should any pathogen be detected in the environment,
including, but not limited to, intensified sanitation measures, intensified sampling and testing
cause analysis); and (d) conducting trend analyses by a qualified analyst and reviewed by a
qualified manager;
areas in the vicinity of food contact surfaces) during both routine environmental monitoring and,
when appropriate, investigative environmental monitoring. When the Sanitation Plan and/or
15
Case 1:22-cv-00441 ECF No. 2-1, PageID.39 Filed 05/16/22 Page 16 of 33
ensure that swabs are collected from Zone 1 (i.e., food-contact surfaces): (a) after such
equipment is disassembled, before being cleaned and sanitized; and (b) after the equipment is
cleaned and sanitized. Defendants shall also ensure that, if any Cronobacter spp. or Salmonella
spp. is detected in a Zone 3 environment (i.e., areas surrounding Zone 2 areas), additional swabs
shall speciate each Cronobacter spp. isolate to determine whether it is Cronobacter sakazakii,
and forward each Cronobacter sakazakii-positive test result to FDA within twenty-four hours of
Salmonella spp. isolate under appropriate storage conditions for three years from the date of the
test result detecting the presence of Cronobacter sakazakii and/or Salmonella spp. in that isolate,
and each isolate is to be provided to FDA within five days of receipt of written request;
with the Product Monitoring Plan, to ensure that controls are adequate to prevent contamination
by pathogens, including Cronobacter spp. and Salmonella spp. Defendants’ Product Monitoring
the beginning, middle, and end (i.e., three separate sampling periods) of each lot of each batch of
implemented should any Cronobacter spp. or Salmonella spp. be detected in any article of food
(including raw ingredients and in-process and finished product batches). As part of the Product
16
Case 1:22-cv-00441 ECF No. 2-1, PageID.40 Filed 05/16/22 Page 17 of 33
Monitoring Plan’s remedial action, if any test of in-process or finished product detects the
event, no later than the completion of any batch then in progress, dispose of the affected in-
(i.e., root-cause analysis), adequately remediate the processing equipment and environment, and
conduct intensified sanitation measures and intensified sampling and testing measures.
Defendants shall maintain records of all these steps and shall make those records available to
FDA immediately upon request. After a cessation of production pursuant to this paragraph,
Defendants shall not resume production unless and until they receive written notice from FDA
that Defendants may resume production. Within fifteen days after receipt of Defendants’ written
request to resume production, unless FDA determines that, based on the complexity of the issues,
a longer time frame is necessary, in which case FDA can give Defendants notice that FDA needs
an additional fifteen days to complete its review, FDA will review Defendants’ request to resume
explaining the basis for FDA’s decision not to permit resumption of production, including the
concerns with Defendants’ submission. After addressing all concerns described in FDA’s
written notification of a decision not to permit resumption, Defendants may submit a new request
to resume production, and the process described in paragraph 11(H)(2)(a) shall be repeated until
Defendants receive written notification from FDA that they may resume production. In no
Cronobacter spp. and/or Salmonella spp. in in-process and/or finished product to FDA within
17
Case 1:22-cv-00441 ECF No. 2-1, PageID.41 Filed 05/16/22 Page 18 of 33
twenty-four hours after receipt by Defendants (along with a written statement confirming that
Defendants have ceased production in accordance with paragraph 11(H)(2)(a)), speciate each
Cronobacter spp. isolate to determine whether it is Cronobacter sakazakii, and forward each
Defendants; and
isolate under appropriate storage conditions for three years from the date of the test result
detecting the presence of Cronobacter sakazakii and/or Salmonella spp. in that isolate, and each
I. Defendants shall prepare a plan that assesses the need for any repair of
buildings (such as roofs) and/or equipment (such as spray dryers), including a determination
whether to continue repairing or replace that equipment. Defendants shall submit the plan to
FDA within four months after receiving written notification from FDA under paragraph 9(D). If
applicable, Defendants may refer to any completed or ongoing action described in Defendants’
J. In the event that Defendants decide to transfer any of their equipment that
is used for production of powdered products from the Sturgis Facility to any other manufacturing
site, Defendants shall notify FDA in writing at least forty-five days prior to the planned transfer.
Defendants’ notification shall include, but not be limited to, a plan for cleaning and sanitizing,
and refurbishing if necessary, the equipment, followed by environmental testing for pathogens,
prior to the transfer of equipment to any other manufacturing site. Defendants shall not transfer
any such equipment unless and until they: (a) receive written concurrence from FDA on the plan
to clean, sanitize, and refurbish the equipment; (b) clean, sanitize, and refurbish the equipment in
18
Case 1:22-cv-00441 ECF No. 2-1, PageID.42 Filed 05/16/22 Page 19 of 33
accordance with the FDA-concurred plan; (c) submit to FDA a detailed written report, with
supporting documentation, describing the actions taken to comply with paragraph 11(J); and (d)
receive written notification from FDA that Defendants appear to be in compliance with
paragraph 11(J);
who shall meet the criteria for and may be the same person as the Expert described in paragraph
8(A), to conduct audit inspections at the Sturgis Facility of the facilities, methods, processes, and
controls used to receive, prepare, process, pack, label, hold, or distribute articles of food.
Defendants shall notify FDA in writing of the identity and qualifications of the Auditor within
two days after retaining the Auditor. Defendants shall ensure that the audit inspections are
conducted as follows:
(1) Defendants shall ensure that, within six months after Defendants
resume operations after receiving FDA’s written notification pursuant to paragraph 9(D), the
Auditor shall conduct an audit at the Sturgis Facility of the facilities, methods, processes, and
controls used to receive, manufacture, process, prepare, pack, label, hold, and distribute articles
of food to determine whether Defendants are operating in compliance with this Decree, the Act,
and its implementing regulations, and to identify any deviations from such requirements.
Defendants shall also ensure that the Auditor submits an Audit Report documenting all findings
to Defendants and FDA concurrently, within seven days after completing the audit;
audits no less frequently than once every six months for a period of one year, and then annually
for the next three years, unless FDA informs Defendants in writing that more frequent audit
19
Case 1:22-cv-00441 ECF No. 2-1, PageID.43 Filed 05/16/22 Page 20 of 33
inspections and reporting are required. If any Audit Report identifies any deviation from this
Decree, the Act, or its implementing regulations, FDA may require the audit cycle be extended;
(3) Defendants shall ensure that, as part of every Audit Report (except
the first one), the Auditor assesses the adequacy of actions taken by Defendants to correct all
previous audit observations, if any, indicating that Defendants are not in compliance with this
Decree, the Act, or its implementing regulations. If the Audit Report contains any audit
observations indicating that Defendants are not in compliance with this Decree, the Act, or its
implementing regulations, Defendants shall make all necessary corrections within ten days after
receipt of the Audit Report, unless FDA notifies Defendants in writing that a shorter time period
is necessary or, upon written request by Defendants and/or based on the nature of the correction
(4) Defendants shall ensure that, within twenty days after the required
completion date for any corrective action under this paragraph, the Auditor reviews each and all
corrective action(s) taken by Defendants and reports in writing to FDA whether each deviation
L. In the event that the Expert or the Auditor determines that the Sanitation
Plan, the Environmental Monitoring Plan, the Product Monitoring Plan, or the Employee
(1) Ensure that the Expert or Auditor reviews the proposed changes
and certifies in writing that the proposed changes establish methods, processes, and controls at
the Sturgis Facility that are adequate to ensure that articles of food are manufactured, processed,
prepared, packed, labeled, held, and distributed in compliance with this Decree, the Act, and
20
Case 1:22-cv-00441 ECF No. 2-1, PageID.44 Filed 05/16/22 Page 21 of 33
with supporting documentation is submitted to Defendants and FDA concurrently, within five
Monitoring Plan, the Product Monitoring Plan, and/or the Employee Training Program, within
certification. Any change to the Sanitation Plan, the Environmental Monitoring Plan, and/or the
Product Monitoring Plan shall ensure that pathogens, including Cronobacter spp. and Salmonella
notify FDA within five days after such termination and immediately retain another expert who
meets the qualifications of the Expert described in paragraph 8(A). Defendants shall notify FDA
in writing of the identity and qualifications of the new Expert within five days after retaining the
shall notify FDA within five days after such termination and immediately retain another expert
who meets the qualifications of the Auditor described in paragraph 11(K). Defendants shall
notify FDA in writing of the identity and qualifications of the new Auditor within five days after
12. Defendants and all Associated Persons who have received actual notice of this
Decree are permanently restrained and enjoined under 21 U.S.C. § 332(a) from directly or
indirectly doing or causing to be done any act at or from the Sturgis Facility that:
21
Case 1:22-cv-00441 ECF No. 2-1, PageID.45 Filed 05/16/22 Page 22 of 33
delivering or causing to be delivered for introduction, into interstate commerce articles of food
delivering or causing to be delivered for introduction, into interstate commerce articles of food,
namely infant formula as defined in 21 U.S.C. § 321(z), that are adulterated within the meaning
of 21 U.S.C. § 350a(a)(3);
C. Violates 21 U.S.C. § 331(k) by causing articles of food that are held for
sale after shipment of one or more of their components in interstate commerce to become
formula as defined in 21 U.S.C. § 321(z), that are held for sale after shipment of one or more of
their components in interstate commerce to become adulterated within the meaning of 21 U.S.C.
§ 350a(a)(3); and/or
13. If, at any time after this entry of this Decree, FDA determines, based on the
Defendants, the Expert(s), or the Auditor, or any other information, that Defendants have failed
to comply with any provision of this Decree, violated the Act or its implementing regulations, or
that additional corrective actions are necessary to achieve compliance with this Decree, the Act,
or its implementing regulations, FDA may, as and when it deems necessary, notify Defendants in
writing of the noncompliance and order Defendants to take appropriate corrective action,
22
Case 1:22-cv-00441 ECF No. 2-1, PageID.46 Filed 05/16/22 Page 23 of 33
including, but not limited to, ordering Defendants to immediately take one or more of the
following actions, which remedies shall be separate and apart from, and in addition to, any other
remedy available to the United States under this Decree or under the law:
B. Recall, at Defendants’ expense, any and all articles of food that have been
distributed or are under the custody and control of Defendants’ agents, distributors, customers, or
consumers that, in FDA’s judgment, are adulterated or otherwise in violation of this Decree, the
Act, or its implementing regulations. Defendants shall initiate the recall(s) within twenty-four
ingredients and in-process and finished products) that are in Defendants’ possession, custody, or
control. Defendants shall bear the costs of destruction and the costs of FDA’s supervision at the
rates specified in paragraph 18. Defendants shall be responsible for ensuring that the destruction
is carried out in a manner that complies with all applicable federal and state environmental laws,
and any other applicable federal or state law. To the extent that Defendants are under a separate
legal obligation to preserve all or a portion of such articles of food, Defendants shall be
permitted to segregate and retain such articles of food for the duration of such preservation
obligation;
23
Case 1:22-cv-00441 ECF No. 2-1, PageID.47 Filed 05/16/22 Page 24 of 33
necessary to protect the public health or bring Defendants into compliance with this Decree, the
Any cessation of operations or other action described in this paragraph shall continue
until Defendants receive written notification from FDA that Defendants appear to be in
compliance with this Decree, the Act, and its implementing regulations. Upon Defendants’
written request to resume operations, FDA will determine whether Defendants appear to be in
such compliance, and, if so, issue to Defendants a written notification permitting, as appropriate,
resumption of operations. Within twenty days after receipt of Defendants’ written request to
resume production, unless FDA determines that, based on the complexity of the issues, a longer
time frame is necessary, in which case FDA can give Defendants notice that FDA needs an
additional twenty days to complete its review, FDA will review Defendants’ request to resume
explaining the basis for FDA’s decision not to permit resumption of production, including the
concerns with Defendants’ submission. After addressing all concerns described in FDA’s
written notification of a decision not to permit resumption, Defendants may submit a new request
to resume production, and the process described in paragraph 13(I) shall be repeated until
Defendants receive written notification from FDA that they may resume production. In no
circumstance shall FDA’s silence be construed as a substitute for written notification. The cost
of FDA inspections, investigations, supervision, examinations, sampling, testing, travel time, and
subsistence expenses to implement and monitor the remedies set forth in this paragraph shall be
24
Case 1:22-cv-00441 ECF No. 2-1, PageID.48 Filed 05/16/22 Page 25 of 33
borne by Defendants at the rates specified in paragraph 17. This provision shall be separate and
apart from, and in addition to, all other remedies available to FDA.
14. If FDA issues a directive pursuant to paragraph 13, the following process and
ten days after receiving such directive, Defendants shall notify FDA in writing either that: (1)
Defendants are undertaking or have undertaken corrective action, in which event Defendants
shall also describe the specific action taken or proposed to be taken and the proposed schedule
for completing the action; or (2) Defendants do not agree with FDA’s directive. If Defendants
notify FDA that they do not agree with FDA’s directive, Defendants shall explain in writing the
basis for their disagreement and, in doing so, may provide specific alternative actions and time
frames for achieving FDA’s objectives. After receipt of Defendants’ notification and
explanation, FDA will review Defendants’ notification and explanation and, in writing, affirm,
modify, or withdraw its directive, as FDA deems appropriate. If FDA affirms or modifies its
directive, it will explain the basis for its decision in writing. The written notice of affirmation or
modification shall constitute final agency action. If FDA affirms or modifies its directive,
Defendants shall, upon receipt of FDA’s affirmed or modified directive, immediately implement
it, and may, if Defendants so choose, bring the matter before this Court. While seeking Court
review, Defendants shall continue to implement and fully comply with FDA’s directive, unless
and until the Court stays, reverses, or modifies FDA’s directive. Any judicial review of FDA’s
directive under this paragraph shall be made pursuant to paragraph 25; and
B. The process and procedures in paragraph 14(A) shall not apply to any
directive issued pursuant to paragraph 13 if such directive states that, in FDA’s judgment, the
25
Case 1:22-cv-00441 ECF No. 2-1, PageID.49 Filed 05/16/22 Page 26 of 33
matter raises a significant public health concern. In such case, Defendants shall, upon receipt of
such directive, immediately and fully comply with the terms of that directive, and the directive
shall be a final agency decision. Should Defendants seek to challenge any such directive, they
may petition the Court for relief while they implement FDA’s directive. Any judicial review of
FDA’s directive under this paragraph shall be made pursuant to paragraph 25.
15. Representatives of FDA shall be permitted, without prior notice and as and when
FDA deems necessary, to inspect the Sturgis Facility, collect samples, and, without prior notice,
take any other measures necessary to monitor and ensure continuing compliance with the terms
of this Decree, the Act, and implementing regulations. During such inspections, FDA
representatives shall be permitted to: have immediate access to the Sturgis Facility and/or other
place(s) of business including, but not limited to, all buildings or other structures, equipment,
raw ingredients, in-process materials, unfinished and finished materials and products, containers,
and labeling; take photographs and make video recordings; take samples, without charge to
FDA, of raw ingredients, in-process materials, unfinished and finished materials and products,
containers, and labeling; and examine and copy all records relating to the receipt, holding, and
distribution of any and all articles of food and their components. The inspections shall be
permitted upon presentation of a copy of this Decree and appropriate credentials. The inspection
authority granted by this Decree is separate and apart from, and in addition to, the authority to
16. Defendants shall promptly provide any information or records to FDA upon
request regarding the receipt, manufacture, processing, preparing, packing, labeling, holding,
and/or distributing of articles of food. Defendants shall maintain copies of the Sanitation Plan,
the Environmental Monitoring Plan, the Product Monitoring Plan, and the Employee Training
26
Case 1:22-cv-00441 ECF No. 2-1, PageID.50 Filed 05/16/22 Page 27 of 33
Program, along with copies of all records required by such plans and this Decree, at the Sturgis
Facility, in a location where the records are readily available for reference and inspection by
FDA. Defendants shall retain all records referred to in this paragraph for at least three years after
17. Defendants shall pay all costs of FDA’s supervision, inspections, investigations,
analyses, examinations, and reviews that FDA deems necessary to evaluate Defendants’
compliance with this Decree, including all transportation and associated costs for FDA
investigators and experts, at the standard rates prevailing at the time the costs are incurred. As of
the date of entry of this Decree, these rates are: $105.46 per hour or fraction thereof per
representative for inspection and investigative work; $126.24 per hour or fraction thereof per
representative for analytical or review work; $0.59 per mile for travel expenses by automobile;
government rate or the equivalent for travel by air or other means; and the published government
per diem rate for subsistence expenses where necessary. In the event that the standard rates
applicable to FDA supervision of court-ordered compliance are modified, these rates shall be
18. Within five days after the entry of this Decree, Defendants shall post a copy of
this Decree in a common area at the Sturgis Facility, and publish the Decree on an internal
Defendants shall ensure that this Decree remains posted as described herein for as long as this
Decree remains in effect. Within ten days after entry of this Decree, Defendants shall provide to
FDA an affidavit of compliance, signed by a person with personal knowledge of the facts, stating
the fact and manner of compliance with the provisions of this paragraph.
27
Case 1:22-cv-00441 ECF No. 2-1, PageID.51 Filed 05/16/22 Page 28 of 33
19. Within ten days after the entry of this Decree, Defendants shall provide a copy of
this Decree by electronic mail to each and all Associated Persons. Within twenty days after the
date of entry of this Decree, Defendants shall provide to FDA an affidavit of compliance, signed
by a person with personal knowledge of the facts, stating the fact and manner of compliance with
the provisions of this paragraph and identifying the names, addresses, and positions of all
persons who have received a copy of this Decree pursuant to this paragraph. Within seven days
after receiving a request from FDA for any information or documentation that FDA deems
necessary to evaluate Defendants’ compliance with this paragraph, Defendants shall provide
20. Within fifteen days after entry of this Decree, Defendants shall hold a general
meeting or series of smaller meetings for all Associated Persons, at which they shall describe the
terms and obligations of this Decree. Within twenty days after entry of this Decree, Defendants
shall provide to FDA an affidavit of compliance, signed by a person with personal knowledge of
the facts, stating the fact and manner of compliance with the provisions of this paragraph and a
copy of the agenda, list of attendees, and meeting minutes from the meeting(s) held pursuant to
this paragraph.
21. In the event that any Defendant becomes associated with any additional
Associated Person(s) at any time after entry of this Decree, Defendants shall immediately
provide a copy of this Decree by electronic mail to such Associated Person(s). On a quarterly
basis, Defendants shall provide to FDA an affidavit of compliance, signed by a person with
personal knowledge of the facts, stating the fact and manner of compliance with the provisions of
this paragraph and identifying the names, addresses, and positions of the additional Associated
Person(s) who have received a copy of this Decree pursuant to this paragraph. Within seven
28
Case 1:22-cv-00441 ECF No. 2-1, PageID.52 Filed 05/16/22 Page 29 of 33
days after receiving a request from FDA for any information or documentation that FDA deems
necessary to evaluate Defendants’ compliance with this paragraph, Defendants shall provide
22. Defendants shall notify FDA in writing at least thirty days before any change in
ownership, name, or character of their business at the Sturgis Facility that occurs after entry of
this Decree including, but not limited to, any of the following, if they may affect obligations
creation or dissolution of subsidiaries; the creation of any additional entities that engage in the
manufacture and distribution of articles of food; the discontinuation of any line of powdered
product; and any other change in the structure or identity of Abbott Nutrition or change in the
responsibility of any individual defendant that affects the Sturgis Facility; and (2) the sale or
assignment of any business assets, such as buildings, equipment, or inventory. Defendants shall
provide a copy of this Decree to any prospective successor or assign at least twenty days before
any sale or assignment. Defendants shall furnish FDA with an affidavit of compliance with this
paragraph no later than ten days before any such assignment or change in ownership.
23. If any Defendant fails to comply with any provision of this Decree, the Act, or its
implementing regulations, including any time frame imposed by this Decree, then Defendants
shall pay to the United States of America thirty thousand dollars ($30,000) in liquidated damages
for each day such violation continues. The total amount of such liquidated damages shall not
exceed five million dollars ($5,000,000) annually. The remedy in this paragraph shall be in
addition to any other remedies available to the United States under this Decree or the law.
29
Case 1:22-cv-00441 ECF No. 2-1, PageID.53 Filed 05/16/22 Page 30 of 33
24. Should the United States bring and prevail in a contempt action to enforce the
terms of this Decree, Defendants shall, in addition to other remedies, reimburse the United States
for its attorneys’ fees (including overhead), travel expenses incurred by attorneys and witnesses,
investigational and analytical expenses, expert witness fees, administrative and court costs, and
any other costs or fees incurred by the United States in bringing such an action.
25. Defendants shall abide by the decisions of FDA, and FDA’s decisions shall be
final. All decisions conferred upon FDA in this Decree shall be vested in FDA’s discretion and,
to the extent that these decisions are subject to review, shall be reviewed by this Court under the
arbitrary and capricious standard set forth in 5 U.S.C. § 706(2)(A). Review by the Court of any
FDA decision rendered pursuant to this Decree shall be based exclusively on the written record
before FDA at the time the decision was made. No discovery shall be taken by either party.
communications to FDA required by the terms of this Decree shall be prominently marked
“Consent Decree Correspondence,” shall reference this civil action by case name and civil action
number, and shall be submitted electronically to the Program Division Director, Office of
Human and Animal Food Operations, Human and Animal Food Division East 6, at
27. This Decree shall apply only to Defendants and Associated Persons, as defined in
paragraph 7(A), involved with the manufacture, processing, preparing, packing, labeling,
30
Case 1:22-cv-00441 ECF No. 2-1, PageID.54 Filed 05/16/22 Page 31 of 33
28. No sooner than sixty months after resuming production after receipt of written
notification from FDA under paragraph 9(D), Defendants may provide written notice to FDA
that they seek relief from this Decree. If, at the time of such notice, in FDA’s judgment
Defendants have maintained a state of continuous compliance with the terms of this Decree, the
Act, and all applicable laws and regulations for at least sixty months after resuming production
after receipt of written notification from FDA under paragraph 9(D), the Defendants may petition
the Court to grant such relief and the United States will not oppose Defendants’ petition.
29. This Court retains jurisdiction over this action and the parties thereto for the
purpose of enforcing and modifying this Decree and for the purpose of granting such additional
31
Case 1:22-cv-00441 ECF No. 2-1, PageID.55 Filed 05/16/22 Page 32 of 33
Case 1:22-cv-00441 ECF No. 2-1, PageID.56 Filed 05/16/22 Page 33 of 33
OF COUNSEL:
DANIEL J. BARRY
Acting General Counsel
Department of Health and Human Services
MARK RAZA
Chief Counsel
Food and Drug Administration
PERHAM GORJI
Deputy Chief Counsel for Litigation
CLAUDIA J. ZUCKERMAN
Senior Counsel
Office of the Chief Counsel
Food and Drug Administration
10903 New Hampshire Avenue
Bldg. 31, Rm 4550
Silver Spring, MD 20993-0002
33